1 / 33

Disclosure

The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood. Disclosure.

polly
Download Presentation

Disclosure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood

  2. Disclosure • Disclosure of Affiliations and Significant Relationships:Dr. Smith has received honoraria related to speakers' bureau activities from Abbott, Merck, Merck Schering-Plough, Schering-Plough, and AstraZeneca. • Disclosure of Unlabeled Use and Investigational Product Discussions:Dr. Smith has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.

  3. RF 6 year old boy.Mother now 44: CABG, age 20, multiple ongoing PCI’s with latest to left main and SVG; bilateral carotid endarterectomies, age 31; on Crestor 40, Niaspan 2000, Zetia 10 and biweekly LDL apheresis.Baseline TC 682, TG 94, HDLC 47, LDLC 623, T/HDL 13.2, Lp(a) 47 (nl < 30).Father: nl lipidsHT: 3’ 11” (35% ile, was 10th) WT: 46lbs. (25% ile, was 5th) BP: 90/60 No xanthomas. Lp(a) = 98 (< 75nmol/L) usCRP = 0.1

  4. DZ 17 yr old young ladyHypertriglyceridemia on diet very low in saturated fatOn Estrostep(Estradiol 20-35mcg, norethindrone 1mg) for irregular mensesFather 55 has  TC, TG, no CHD.Mother 52 healthy but maternal grandmother MI –age 52.Sister age 22 with similar lipids.PE: 5’ 4” WT: 118lbs (IW=128bs) BP: 110/64 Lp(a) = 105nmol/L (nl < 75nmol/L us CRP = 2.3mg/dl

  5. The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood Mary P. McGowan, MD Director: Cholesterol Treatment Center Concord Hospital Assistant Professor of Medicine University of Massachusetts Medical Center

  6. Disclosure • Disclosure of Affiliations and Significant Relationships:Dr. McGowan has received honoraria related to speakers' bureau activities from Merck and Co. She has also received honoraria related to consulting and speaking activities from Schering-Plough. • Disclosure of Unlabeled Use and Investigational Product Discussions:Dr. McGowan has indicated that her presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.

  7. Rationale for Retiring 1998 AAP Policy Statement “Cholesterol in Childhood” • The current epidemic of childhood obesity has resulted in an increase in type 2 diabetes, HTN and lipid disorders • Studies have clearly demonstrated that the atherosclerotic process begins in childhood • New data has established the effectiveness and safety of some of the available lipid lowering agents in children as young as 8 years of age. • Pediatrics 1998;101(1pt1):141-147 • Pediatrics 2008;122:198-208

  8. Evidence for Atherosclerosis Beginning in Childhood • Fatty streak formation occurs in human fetal aortas and is enhanced by maternal hypercholesterolemia (JCI 1997;100:2680-2690) • Bogalusa Heart Study: Fatty streaks at age 3. More frequent in adolescence (NEJM 1986;314:138-144) • Pathobiological Determinants of Atherosclerosis in Youth (PDAY) (N=2876, ages 15-34) Found that the extent of fatty streaks and fibrous plaques in the Ao and Cor arteries is strongly correlated with elevated cholesterol (ATVB 1997;17(1):95-106)

  9. Evidence for Atherosclerosis Beginning in Childhood • Bogalusa Heart Study: Fatty Streaks were present in about 50% of individuals during childhood and in 85% of young adults. • By young adulthood, fibrous plaques were present in 69% of individuals studied. • The extent of atherosclerotic lesions correlated positively with total cholesterol, LDL cholesterol, triglycerides, blood pressure and with body mass index. • The extent of atherosclerotic lesions in childhood was noted to rise exponentially with increasing number of risk factors.(NEJM 1998;338:1650-1656)

  10. Evidence for Atherosclerosis Beginning in Childhood • Bogalusa Heart Study (N=486): Childhood measurement of LDL-C and BMI predict carotid IMT in young adults (JAMA.2003;290:2271-2276) • The Cardiovascular Risk in Young Finns Study (N = 2229): Risk factor profile assessed in 12-18 year olds predicts adult common carotid IMT independently of contemporaneous risk factors. Suggesting that exposure to CVD RF early in life may induce changes in arteries that contribute to the development of atherosclerosis. (JAMA.2003;290:2277-2283)

  11. Cholesterol Concentrations in Youth • Cholesterol levels at birth: TC 70 mg/dL, LDL 30 mg/dL, HDL 35 mg/dL • Cholesterol increases rapidly in the first 2 years of life • Mean TC peaks at 171 mg/dL between ages 9-11 • Cholesterol levels decrease during puberty and increase thereafter • HDL falls permanently in young men during puberty • Ethnic differences: Black children--higher HDL/lower TG than Hispanics or non-Hispanic whites • J Chronic Dis. 1981;34(1)27-39. Prev Med.1998;27(6):879-890

  12. Cholesterol Concentrations in Youth • Elevated concentrations of lipids and lipoproteins are quite common. In the Child and Adolescent Trial for Cardiovascular Health (grades 3 – 4) the prevalence of total cholesterol concentrations > 200 mg/dL was 15.6% in girls and 11.1% in boys. Am J Epidemiol 1995;141(5):428-439. • 75% of children in the Muscatine Study and 70% of children in the Bogalusa Heart Study with elevated lipids tracked into adulthood. JAMA 1990;264(23):3034-3038 & Am J Epidemiol 1991;133:(9)884-899.

  13. Primary preventionWhat does a 20 – 40 mg/dL lower LDL cholesterol mean over 4 – 5 decades?

  14. Atherosclerosis Risk in Communities Study (ARIC)LDLC andProprotein Convertase subtilisin/kexin type 9 (PCSK9) serine protease gene variants that increase LDL receptors15 year follow up: MI fatal CHD revascularization in 13,000 Americans in 4 communities age 40 – 55 yrs Cohen JC et al. NE5M 2006;354:1264.

  15. Atherosclerosis Risk in Communities Study3363 African Americans vs 85 carriers PCSK9 142X or 679X LDL-C 138 LDL-C 100 HR .12, p 0.03 (90% risk reduction) NNT 12 Cohen JC et al. NEJM 2006;354:1264.

  16. Atherosclerosis Risk in Communities Study 9923 Caucasians vs 301 carriers PCSK9 46L LDL-C 137 LDL-C 116 HR 0.50, p 0.003 (50% risk reduction) NNT = 20 Cohen JC et al. NEJM 2006;354:1264.

  17. Conclusion: genes that reduce LDL cholesterol 20 to 40 mg/dL Can result in 50 to 90% reductions in ischemic CV events in Americans in their fifth and sixth decades

  18. Screening • Current AAP Clinical Report offers no new guidance on whom to screen. • NCEP Guidelines 1992 advocate a targeted approach: screen children with • family hx of CVD • elevated chol • family hx unknown • Presence of other CVD RF (obesity, cig smoking, htn, DM)

  19. Targeted Approach to Screening • Targeted approach results in between 35-46% of children being screened • Studies suggest that 30-60% of children and adolescents with elevated cholesterol are likely to be missed with a targeted approach - Does this lead to an increase in CVD in adulthood? • Pediatrics 1996;98(3 pt 1):383-388 • J pediatr 1995;126(3):345-352 • Pediatrics 1989;84(2):365-373

  20. NCEP Cut Points for TC and LDL in YouthPediatrics 1992;89(3 pt 2)525-584

  21. Abnormal Cholesterol Levels • Current AAP report notes that the NCEP guidelines use the same cut points for all children ages 2-18 • Sensitivity and specificity of these cut points to predict adult lipid status may vary according to age and sexual maturation • One study suggested lowest sensitivity between 14-16 yrs, and highest sensitivity between 5-10 and 17 – 19 yrs. (pediatrics 2006;118(1)165-172) • Offers a suggestion that guidelines from LRC pediatric Prevalence Study might be used – but these guidelines reported in 1981 before current obesity epidemic and all-white population studied

  22. New AAP Report and Abnormal Cholesterol Levels • NCEP guidelines: no pediatric cut points for TG or HDL. With the epidemic of pediatric obesity these lipoprotein parameters have become important. • Cites AHA recommendation (J Pediatr2003;142:368-372) • Triglyceride concentrations of > 150 mg/dL* • HDL concentration < 35 mg/dL** as abnormal • Single cut point for TG or HDL may be of limited use given age, sexual and ethnic differences in these lipoproteins offers LRC Pediatric Prevalence Study for consideration * > 95th percentile for any age or sex ** < 5th percentile for any age or sex

  23. Approach to the treatment of Lipid Abnormalities in Youth • Population Approach: Current AAP report concurs with previous guidelines recommending that • children / adolescents have a balanced caloric intake • sufficient physical activity to achieve appropriate weight • more fruits, vegetables, fish, whole grains low fat dairy products • reduced fruit juice, sugar-sweetened beverages/foods, salt • Trans fats < 1% of calories • New in these recommendations: • Children between 12 months and 2 years for whom overweight or obesity is a concern or who have a family hx. of obesity, dyslipidemia or CVD • reduced fat milk would be appropriate

  24. Approach to the treatment of Lipid Abnormalities in Youth • Individual Approach: Focus on children and adolescents • with a family hx of CVD or hyperlipidemia or • who themselves have elevated cholesterol The diet restricts saturated fat to 7% of calories and dietary cholesterol to < 200 mg/day Involve the entire family and a dietitian • Other approaches in this population: • Fiber (age + 5 g up to 20 grams) • Plant stanols or sterols and • Increased physical activity

  25. Approach to the treatment of Lipid Abnormalities in Youth • Individual Approach: High risk children defined as those having an LDL > 190 mg/dL despite dietary therapy, or LDL > 160 mg/dL with other risk factors or > 130 mg/dL with diabetes are candidates for pharmacologic intervention. This is not a new recommendation • 1992 NCEP recommended these cut points (with exception of the third – did not single out diabetes as a special circ) but did not suggest statins as first line drugs • Circulation 2007;115(14)1948-1967: Statins as first line beginning at age 10 – also added other high risk children including (DM, transplantation, HIV, SLE, nephrotic syndrome) • New in this report: Initiate drug therapy between 8-10

  26. Approach to the treatment of Lipid Abnormalities in Youth • Statins first line therapy in appropriate children statins approved for use in children include: lovastatin, pravastatin, simvastatin, and atorvastatin • Bile Acid – Binding Resins: poor compliance • Niacin: LFT abnormalities reported in up to 26% of children. Pediatrics 1993;92(1)78-82 • Cholesterol-absorption Inhibitors: attractive, not extensively studied • Fibrates: not extensively studied

  27. Summary – New recommendations • Children between 12 months and 2 years of age overweight or obese, or family hx. of obesity, dyslipidemia or CVD reduced fat milk is appropriate • Overweight triggers a full lipid profile • First lipid screening -- after age 2 and before age 10 • Should be done fasting and if normal re-checked every 3-5 years • Overweight/obese children with high TG or low HDL weight management treatment of choice

  28. Summary – New recommendations • Children age 8 years and older meeting cut-points for pharmacological treatment – statins are the drug of first choice

  29. Implications for Practicing Lipidologists • If you do not see children in your practice recommend screening the children of your adult patients. • Our EMR generates a letter sent to pediatricians / family practitioners who care for children of our adult patients • We have two pediatricians on staff in our practice.

  30. The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood Samuel Gidding, MD ProfessorDepartment of PediatricsJefferson Medical CenterDivision HeadNemours Cardiac CenterHaddonfield, NJ

  31. Disclosure • Disclosure of Affiliations and Significant Relationships:Dr. Gidding has disclosed that he has no significant relationships with the grantors or any other commercial company whose products and services are discussed in his presentation. • Disclosure of Unlabeled Use and Investigational Product Discussions:Dr. Gidding has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.

  32. The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood

  33. Questions ?

More Related